Molecular targeted therapy in enteropancreatic neuroendocrine tumors: From biology to clinical practice

Current Medicinal Chemistry

Volumn 21, Issue 8, 2014, Pages 1017-1025

  Fazio, N ^a   Scarpa, A ^b   Falconi, M ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bevacizumab; Everolimus; GEP; Molecular targeted therapies; MTOR; NETs; Neuroendocrine tumors; Sunitinib

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APHTHOUS STOMATITIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPERGLYCEMIA; META ANALYSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEURAL PLATE; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS;

EID: 84896374336     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990237     Document Type: Article

References (57)

1. Modlin, I.M.; Lye, K.D.; Kidd, M. A. 5-decade analysis of 13715 carcinoid tumors. Cancer, 2003, 97, 934-959.
2. Yao, J.C.; Hassan, M.; Phan, A; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26, 3063-3072.
3. Solcia, E.; Kloppel, G.; Sobin, L.H. Histological Typing of Endocrine Tumours, 2nd ed.; Springer: Berlin, 2000.
4. Bosman, F.; Carneiro, F.; Hruban, R.; Theise, N. WHO Classification of Tumours of the Digestive System. IARC: Lyon, France, 2010.
5. Öberg, K.; Funa, K.; Alm, G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N. Engl. J. Med., 1983, 309, 129-133.
6. Wood, S.M.; Kraenzlin, M.E.; Adrian, T.E.; Bloom, S.R. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: symptomatic and peptide responses. Gut, 1985, 26, 438-444.
7. Terris, B.; Scoazec, J.Y.; Rubbia, L.; Bregeaud, L.; Pepper, M.S.; Ruszniewski, P.; Belghiti, J.; Fléjou, J.; Degott. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology, 1998, 32, 133-138.
8. Chaudhry, A.; Funa, K.; Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta. Oncol., 1993, 32, 107-114.
9. Nilsson, O.; Wängberg, B.; Theodorsson, E.; Skottner, A.; Ahlman, H. Presence of IGF-I in human midgut carcinoid tumours - an autocrine regulator of carcinoid tumour growth? Int. J. Cancer., 1992, 51, 195-203.
10. Shah, T.; Hochhauser, D.; Frow, R.; Quaglia, A.; Dhillon, A.P.; Caplin, M.E. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol., 2006, 18, 355-360.
11. Funa, K.; Papanicolaou, V.; Juhlin, C.; Rastad, J.; Akerström, G.; Heldin, C.H.; Oberg, K. Expression of platelet derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res, 1990, 50, 748-753.
12. Lopez, T.; Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2002, 1, 339-353.
13. Fjällskog, M.L.; Lejonklou, M.H.; Oberg, K.E.; Eriksson, B.K.; Janson, E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin. Cancer. Res., 2003, 9, 1469-1473.
14. Perren, A.; Komminoth, P.; Saremaslani, P.; Matter, C.; Feurer, S.; Lees, J.A.; Heitz, P.U.; Eng, C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol, 2000, 157, 1097-1103.
15. Karhoff, D.; Sauer, S.; Schrader, J.; Arnold, R.; Fendrich, V.; Bartsch, D.K.; Hörsch, D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology, 2007, 85, 45-53.
16. Duerr, E.M.;Mizukami, Y.; Ng, A.; Xavier, R.J.; Kikuchi, H.; Deshpande, V.; Warshaw, A.L.; Glickman, J.; Kulke, M.H.; Chung, D. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. End. Rel. Cancer., 2008, 15, 243-256.
17. Corbo, V.; Dalai, I.; Scardoni, M.; Barbi, S.; Beghelli, S.; Bersani, S.; Albarello, L.; Doglioni, C.; Schott, C.; Capelli, P.; Chilosi, M.; Boninsegna, L.; Becker K.F.; Falconi, M.; Scarpa. A.MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. End. Rel. Cancer., 2010, 17, 771-783.
18. Jiao, Y.; Shi, C.; Edil, B.H.; de Wilde, R.F.; Klimstra, D.S.; Maitra, A.; Schulick, R.D.; Tang, L.H.; Wolfgang, C.L.; Choti, M.A.; Velculescu, V.E.; Diaz, L.A. Jr.; Vogelstein, B.; Kinzler, K.W. Hruban, R.H.; Papadopoulos, N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 2011, 331(6021), 1199-1203.
19. Patel, Y.C. Somatostatin and its receptor family. Front Neuroendocrinol, 1999, 20, 157-198.
20. Papotti, M.; Bongiovanni, M.; Volante, M.; Allia, E.; Landolfi, S.; Helboe, L.; Schindler, M.; Cole, S.L. & Bussolati, G. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv, 2002, 440 461-475.
21. Miederer, M.; Seidl, S.; Buck, A.; Scheidhauer, K.; Wester, H.J.; Schwaiger, M.; Perren, A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT . Eur. J. Nucl. Med. Mol. Imaging., 2009, 36, 48-52.
22. Bruns, C.; Lewis, I.; Briner, U.; Meno-Tetang, G.; Weckbecker, G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrino, 2002, 146, 707-716.
23. Kvols, L.; Oberg, K.E.; O'Dorisio, T.M.; Mohideen, P.; de Herder, W.W.; Arnold, R.; Hu. K.; Zhang. Y.; Hughes, G.; Anthony, L.; Wiedenmann B. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer, 2012, 19(5), 657-666.
24. Averous, J.; Proud, C.G.; When translation meets transformation: the mTOR story. Oncogene, 2006, 25, 6423-6435.
25. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene, 2006, 25, 6436-6446.
26. Land, S.C.; Tee, A.R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol Chem, 2007, 282, 20534-20543.
27. Missiaglia, E.; Dalai, I.; Barbi, S.; Beghelli, S.; Falconi, M.; della Peruta, M.; Piemonti, L.; Capurso, G.; Di Florio, A.; delle Fave, G.; Pederzoli, P.; Croce, C.M.; Scarpa, A.; Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol., 2010, 28(2), 245-255.
28. Mita, M.M.; Mita, A.; Rowinsky, E.K. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther, 2003, 4(Suppl. 1), S169-177.
29. Duran, I.; Kortmansky, J.; Singh, D.; Hirte, H.; Kocha, W.; Goss, G.; Le, L.; Oza, A.; Nicklee, T.; Ho, J.; Birle, D.; Pond, G.R.; Arboine, D.; Dancey, J.; Aviel-Ronen, S.; Tsao, M.S.; Hedley, D.; Siu, L.L. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer, 2006, 95, 1148-1154.
30. Charland, S.; Boucher, M.J.; Houde, M.; Rivard, N. Somatostatin inhibits Akt phosphorylation and cell-cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral-pancreatic acinar cells. Endocrinology, 2001, 142, 121-128.
31. Pokrajac, A.; Frystyk, J.; Flyvbjerg, A.; Trainer, P.J. Pituitaryindependent effect of octreotide on IGF1 generation. Eur J Endocrinol, 2009, 160, 543-548.
32. Yao, J.C.; Phan, A.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; Meric-Bernstam, F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate grade neuroendocrine tumours: results of a phase II study. J. Clin. Oncol., 2008, 26, 4311-4318.
33. Yao, J.C.; Lombard-Bohas, C.; Baudin, E.; Kvols, L.K.; Rougier, P.; Ruszniewski, P.; Hoosen, S.; St Peter, J.; Haas, T.; Lebwohl, D.; Van Cutsem, E.; Kulke, M.H.; Hobday, T.J.; O'Dorisio, T.M.; Shah, M.H.; Cadiot, G.; Luppi, G.; Posey, J.A.; Wiedenmann, B. A phase II trial of daily oral RAD001 (everolimus) in patients with metastatic pancreatic neuroendocrine tumors (NETs) after failure of cytotoxic chemotherapy. J. Clin. Oncol., 2010, 28, 69-76.
34. Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.; Tomassetti, P.; Pavel, M.E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Oberg, K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 514-523.
35. Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Horsch. D.; Winkler, R.E. Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.; Oberg, K.; Van Cutsem, E.; Yao, J.C. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, 2011, 378(9808), 2005-2012.
36. Fazio, N.; Granberg, D.; Grossman, A.; Saletan, S.; Klimoski, J.; Panneeservalm, A.; Wolin, E.M. Everolimus Plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumors Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study. Chest, 2012, Sep 10, [Epub ahead of print]
37. Castellano, D.; Bajetta, E.; Panneerselvam, A.; Saletan, S.; Kocha, W.; O'Dorisio, T.; Anthony, L.B.; Hobday, T. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT- 2 Study. Oncologist, 2013, 18(1), 46-53.
38. Iacovelli, R.; Palazzo, A.; Mexi, S.; Morano, F.; Naso, G.; Cortesi, E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol, 2012, 51, 873-879.
39. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 2006, 66(3), 1500-1508.
40. Grozinski-Glasberg, S.; Franchi, G.; Teng, M.; Leontiou, C.A.; Ribeiro de Oliveira, A. Jr.; Dalino, P,; Salahuddin, N.; Korbonits, M.; Grossman, A.B. Octreotide and the mTOR inhbitor RAD001 (Everolimus) block proliferation and interact with the Akt-mTORp70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology, 2008, 87, 168-181.
41. Moreno, A.; Akcakanat, A.; Munsell, M.F.; Soni, A.; Yao, J.C.; Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine related cancer, 2008, 15, 257-266.
42. Svejda, B.; Kidd, M.; Kazberouk, A.; Lawrence, B.; Pfragner, R.; Modlin, I.M. Limitations in small intestinal neuroendocrine tumor therapy by mTOR kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and akt. Cancer, 2011, 117(18), 4141-4154.
43. Meric-Bernstam, F.; Akcakanat, A.; Chen, H.; Do, K.A.; Sangai, T.;Adkins, F.; Gonzalez-Angulo, A.M.; Rashid, A.; Crosby, K.; Dong, M.; Phan, A.T.; Wolff, R.A.; Gupta, S.; Mills, G.B.; Yao, J.; PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clin. Cancer. Res., 2012, 18(6), 1777-1789.
44. Pool, S.E.; Bison, S.; Koelewijn, S.J.; van der Graaf, L.M.; Melis, M.; Krenning, E.P.; de Jong, M. mTOR inhibitor RAD001 promotes metastasis in 1 a rat model of pancreatic neuroendocrine cancer. Cancer Res, 2012, Published Online First November 13.
45. Yao, J.; Phan, Alexandria.; Jehl, Valentine.; Shah, Gaurav.; Meric-Bernstam, F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. J. Clin. Oncol., 2013, published online first February 22.
46. Couvelard, A.; O'Toole, D.; Turley, H.; Leek, R.; Sauvanet, A.; Degott, C.; Rusznieski, P.; Belghiti, J.; Harris, A.L.; Gatter, K.; Pezzella, F. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer., 2005, 92, 94-101.
47. Marion-Audibert, A.M.; Barel, C.; Gouysse, G.; Dumortier, J.; Pilleul, F.; Pourreyron, C.; Hervieu, V.; Poncet, G.; Lombard-Bohas, C.; Chayvialle, J.A.; Partensky, C.; Scoazec, J.Y. Low microvessels density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology, 2003, 125, 1094-1104.
48. Scoazec, J.Y. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology, 2013, 97(1): 45-56.
49. Couvelard, A.; Deschamps, L.; Rebours, V.; Sauvanet, A.; Gatter, K.; Pezzella, F.; Rusznieski, P.; Bedossa, P. Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, anmd FIH is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin. Cancer. Res., 2008, 14, 6634-6639.
50. Teulè, A.; Casanovas, O. Relevance of angiogenesis in neuroendocrine tumors. Targ Oncol, 2012, Jun; 7(2): 93-98.
51. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res, 2003, 9, 327-337.
52. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patient with cancer. J. Clin. Oncol., 2006, 24, 25-35.
53. Kulke, M.H.; Lenz, H.J.; Meropol, N.J.; Posey, J.; Ryan, D.P.; Picus, J.; Bergsland, E.; Stuart, K.; Tye, L.; Huang, X.; Li, J.Z.; Baum, C.M.; Fuchs, C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol., 2008, 26, 3403-3410.
54. Raymond, E.; Dahan, L.; Raoul. J.L.; Bang, Y.J.; Borbath, I.; Lombard-Bohas, C.; Valle, J.; Metrakos, P.; Smith, D.; Vinik, A.; Chen, J.;, Hörsch, D.; Hammel, P.; Wiedenmann, B.; Van Cutsem, E.; Patyna, S.; Lu, D.R.; Blanckmeister, C.; Chao, R.; Ruszniewski, P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 501-513.
55. Choi, H.; Charnsangavej, C.; Faria, S.C.; Macapinlac, H.A.; Burgess, M.A.; Patel, S.R.; Chen, L.L.; Podoloff, D.A.; Benjamin, R.S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol., 2007, 25, 1753-1759.
56. Yao, J.C.; Phan, A.; Hoff, P.M.; Chen, H.X.; Charnsangavej, C.; Yeung, S.C.; Hess, K.; Ng, C.; Abbruzzese, J.L.; Ajani, J.A. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol., 2008, 26, 1316-1323
57. Chan, J.A.; Stuart, K.; Earle, C.C.; Clark, J.W.; Bhargava, P.; Miksad, R.; Blaskowsky, L.; Enzinger, P.C.; Meyerhardt, J.A.; Zheng, H.; Fuchs, C.S.; Kulke, M.H. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol., 2012, 30(24), 2963-2968.